As shown in Figure 3, high expression of FAM111A predicted a remarkably shorter overall survival (OS) both in CGGA (Figures 4A–C) and in TCGA datasets (Figures 4D–F) in LGGs, which included WHO grade II and WHO grade III gliomas. The gene discussed is FAM111A; the disease is central nervous system cancer.